Pharmacy Guide

Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.

Pharmacy Guide

Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.

← Back to all medicines

Synacthen Depot Ampoules 1 mg/ml

⚠ This medicine appears to have been discontinued

The electronic medicines compendium (emc) no longer publishes a Summary of Product Characteristics for this product, which usually means it is no longer marketed in the UK. The patient leaflet below is kept for reference, but the product may not be available.

If you were prescribed this medicine, other products containing Tetracosactide acetate may still be available. Do not stop your treatment — ask your pharmacist or GP what to use instead.

Active substance: Tetracosactide acetate
Source: electronic medicines compendium (emc)
Official leaflet: Read the PIL on emc

What it is and what it is used for

for Synacthen Depot belongs to a group of medicines called pituitary hormones and analogues. The pituitary gland is a small gland inside the brain which controls many other glands in the body, including the thyroid and adrenal glands. The pituitary gland produces hormones which send chemical messages to various parts of the body and affect many bodily functions such as blood pressure, blood sugar levels, growth and menstrual cycle. The adrenal glands are found on top of the kidneys and make the body's natural steroids which can affect blood pressure and the way the body handles the sugars, protein and fats absorbed from food. They also make adrenaline which controls the body's response to different types of stress. Synacthen Depot is similar to the hormone that the pituitary gland normally produces (called ACTH) to make the adrenal glands produce certain steroids. When Synacthen Depot is injected it works on the adrenal glands by 'telling' them to produce more steroids.

Synacthen Depot is used in place of medicines like prednisolone or cortisone (types of steroids) to treat a number of different conditions, including ulcerative colitis, Crohn's disease, rheumatoid arthritis and osteoarthrosis. It is usually only given for a short time. Synacthen Depot is also used as a test to find out if the pituitary and adrenal glands are working normally.

What you need to know before you take it

Synacthen Depot You should not be given Synacthen Depot if:

  • you are allergic (hypersensitive) to adrenocorticotropic hormone (ACTH), tetracosactide acetate or any of the other ingredients of Synacthen Depot (listed in Section 6)
  • you suffer from any allergies, including allergies to any medicines
  • you suffer from asthma
  • you suffer from any serious mood or mental health disorders
  • you have or have ever had tuberculosis
  • you have currently got any infections
  • you suffer from any known hormone problems, e.g. Cushing's syndrome or Addison's disease (over or under active adrenal glands)
  • you have an ulcer in your stomach or small intestine
  • you suffer from any serious heart disease
  • it is for the treatment of primary adrenocortical insufficiency or adrenocongenital syndrome (where your adrenal glands are not working). Warnings and precautions Before you are given Synacthen Depot, tell your doctor or nurse if:
  • you have been vaccinated recently or are planning to have a vaccination
  • your immune system is not working properly
  • you have any disorder of the intestines, e.g. ulcerative colitis, diverticulitis
  • you have recently had surgery on your intestines (bowel)
  • you suffer from high blood pressure
  • you have suffered from a blood clot in the past
  • you suffer from osteoporosis (thinning of the bones)
  • you suffer from myasthenia gravis (an illness causing muscle weakness)
  • you have an under active thyroid gland which can cause tiredness or weight gain
  • you suffer from any serious liver or kidney disease
  • you are pregnant, think you might be pregnant or are breast-feeding
  • you have ocular herpes simplex (viral infection of the eye). If you suffer an injury or have surgery during Synacthen Depot treatment or within one year after the end of the treatment, the Synacthen Depot dose may have to be increased or the Synacthen Depot treatment restarted.

Other medicines and Synacthen Depot Tell your doctor or nurse if you are taking/using, have recently taken/used or might take/use any of the following medicines as they may interfere with Synacthen Depot:

  • medicines to control high blood pressure
  • medicines to control diabetes
  • medicines to control convulsions (fits) such as valproate, phenytoin, clonazepam, nitrazepam, phenobarbital or primidone
  • medicines to control conception (birth control). It may be necessary to change the dose or in some cases to stop the medicine. Please tell your doctor or nurse if you are taking or have recently taken/used any other medicines, including medicines obtained without a prescription. Synacthen Depot with food and drink Since Synacthen Depot can cause salt and water retention, your doctor may advise a low-salt diet during treatment. Pregnancy, breast-feeding and fertility If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or nurse for advice before taking this medicine. Your doctor will discuss with you the potential risk of using Synacthen Depot during pregnancy. Synacthen Depot should be given with caution to women who are breast-feeding. Driving and using machines If you feel dizzy or get blurred vision after you have been given Synacthen Depot, do not drive or operate machinery until these effects have worn off. Synacthen Depot is essentially 'sodium-free' – it contains less than 1 mmol sodium (23 mg) per 1mg.

How to take it

Synacthen Depot Your treatment with Synacthen Depot will take place in a hospital, under the supervision of a doctor. The doctor will be monitoring your progress carefully during your treatment with Synacthen Depot. Your doctor will decide on a suitable dose of Synacthen Depot depending on your condition.

Adults Adults including elderly patients will usually start treatment with 1mg once or twice daily for about three days. As your condition improves, this dose will then be reduced over a period of several weeks, to 0.5mg every two to three days or 1mg once a week Children Children aged 3 -12 years will be given a lower dose based on their age and weight. They will start with an injection every day. This will then be reduced to once every 2 to 8 days. Your doctor may monitor growth or organise heart scans in children who are given this medicine for a long period of time. How should Synacthen Depot be given? The ampoules should be shaken before use. The liquid in the ampoule will be drawn up into a syringe and injected into a muscle by your doctor or nurse (never into a vein). For how long should Synacthen Depot be given? For therapeutic use: Synacthen will not cure your condition but it may relieve some of the symptoms. The injections can be continued for as long as they are beneficial. For diagnostic tests use: You will be given a single injection of Synacthen Depot. You will have six blood samples taken, one before the injection and the others 30 minutes, 1, 2, 3, 4 and 5 hours after the injection. These blood samples will show whether your adrenal glands are functioning as well as they should. What to do if you think you have received more Synacthen Depot than you should As this medicine is given to you in hospital, it is very unlikely that an overdose will happen. If anyone receives this medicine by accident, tell the hospital accident and emergency department or a doctor immediately. Show any left over medicines or the empty packet to the doctor. If you forget to take Synacthen Depot As a doctor or nurse is giving you this medicine, you are unlikely to miss a dose. If you have any worries, tell a doctor or nurse. 4. Possible side effects Like all medicines, Synacthen Depot can cause side effects, although not everyone gets them. Serious side effects:

•

• • • • •

Anaphylactic shock or severe allergic reaction (symptoms may include redness or pain at the injection site, rash, itching, hives or flushing, dizziness, feeling or being sick, difficulty breathing, and swelling of the face, lips, tongue or other parts of the body, feeling unwell). This tends to be more severe in people, who suffer from allergies (especially asthma). For this reason, you should be monitored carefully for 30 minutes after each injection. If you get a reaction like this when you are not under medical supervision, contact your doctor or nearest hospital accident and emergency department immediately. Once you have had an allergic reaction like this, you should never be treated with Synacthen Depot or similar medicines again. bleeding of the adrenal gland (small glands above the kidneys) which may result in sudden pain in the stomach and back, weakness, fainting, loss of appetite and feeling or actually being sick blood clot (symptoms may include pain, swelling, redness, warmth and tenderness in the area of the clot depending on location in the body) blood in your stools blood in your urine blood in your vomit.

If you experience any of these at any time, tell your doctor straight away or go immediately to the nearest hospital accident and emergency department. Side effects which may occur with Synacthen Depot include the following:

  • itching
  • menstrual (period) problems
  • inflammation of the pancreas
  • swelling of the face (moon face) which causes severe stomach
  • increased thirst and back pain
  • mood changes or fits • acne, other skin problems or
  • decreased or blurred vision unusual bruising
  • high blood pressure • muscle cramps or pain, muscle
  • heart problems which can cause weakness shortness of breath or ankle • pain in back, hips, arms, swelling shoulders or legs
  • inflammation of the blood vessels
  • poor healing of wounds (sometimes with a rash, arthritis
  • increased chance of infection or kidney failure) • •

•

abscess increase in the number of white blood cells which can cause bleeding, fever, infection or inflammation unusual increase in hair growth on body or face

• • • •

diabetes mellitus (increased sugar levels in your blood and urine) fluid retention sodium retention low levels of potassium which can cause muscle weakness, muscle twitching or abnormal heart beat or low levels of

• • • • • • • • • •

calcium which can cause muscle cramps, stomach cramps or spasms. Your doctor may want to take a blood test to measure your blood levels of potassium or calcium increased appetite headache protrusion of the eye-balls in their sockets glaucoma/blurred vision thinning of skin a feeling of dizziness or "spinning" stomach pain or a bloated stomach inflammation of the gullet (food pipe)

• • • • • • • •

• •

small, round, dark red spots on the skin bruising facial flushing darkening or lightening of skin colour increased sweating bone thinning and fractures of the bones hormonal imbalance ruptured tendon, the symptoms of which include severe pain, inability to use the affected arm or leg and rapid bruising at the site slowing of the rate of growth in children weight increase

long term use in children up to 5 years may cause changes to the heart may affect the results of skin prick test reactions.

Reporting of suspected adverse reactions If you get any side effects, talk to your doctor or nurse. This includes any

Possible side effects

not listed in this leaflet. You can also report side effects directly via the Yellow Card Scheme by connecting to the following website: www.mhra.gov.uk/yellowcard. By reporting side effects you can help provide more information on the safety of this medicine.

How to store it

Synacthen Depot Synacthen Depot will be stored in the hospital pharmacy. Keep out of the sight and reach of children. Do not use Synacthen Depot after the expiry date which is stated on the ampoule and the carton. The expiry date refers to the last day of that month after EXP. Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer require. These measures will help protect the environment.

Contents of the pack and other information

What Synacthen Depot contains

The active substance of Synacthen Depot is tetracosactide (as acetate) 1 mg per ampoule. The other ingredients are zinc chloride anhydrous pure, disodium phosphate dodecahydrate, sodium chloride, sodium hydroxide and water for injections. What Synacthen Depot looks like and contents of the pack Synacthen Depot is a sterile, milky white suspension in a 1 mL (millilitre) clear glass ampoule. Synacthen Depot comes in packs of 1 ampoule and 10 ampoules. Not all pack sizes may be marketed. Marketing Authorisation Holder: Atnahs Pharma UK Limited, Sovereign House, Miles Gray Road, Basildon, Essex, SS14 3FR, United Kindom Manufacturer: Waymade Plc, Sovereign House, Miles Gray Road, Basildon, Essex, SS14 3FR, United Kingdom Atnahs Pharma UK Limited, Sovereign House, Miles Gray Road, Basildon, Essex, SS14 3FR, United Kingdom Misom Labs Limited, Malta Life Sciences Park, LS2.01.06 Industrial Estate, San Gwann, SGN 3000, Malta The information in this leaflet applies only to Synacthen Depot. If you have any questions or you are not sure about anything, ask your doctor or a nurse. This leaflet was last revised in: January 2025. © Atnahs Pharma UK Ltd. SYNACTHEN is a registered trademark of Novartis AG and is used under licence by Atnahs Pharma UK Ltd.

<———————————————————————————————————-> The following information is intended for healthcare professionals only: Synacthen Depot should be shaken before use. Synacthen Depot must be injected intramuscularly (i.m.) by a doctor or a nurse. Synacthen Depot must not be injected intravenously. 1. Dosage Indication

Method of administration

Therapeutic use:

Initially, daily doses of Synacthen Depot should be given but after approximately 3 days, intermittent doses may be given. Adults: Initially 1mg intramuscularly daily or 1mg every 12 hours in acute cases. After the acute symptoms of the disease have disappeared, treatment may be continued at a dose of 1mg every 2 to 3 days; in patients who respond well, the dosage may be reduced to 0.5mg every 2 to 3 days or 1mg per week. Children aged 3 to 5 years: Initially 0.25 to 0.5mg administered intramuscularly daily; the maintenance dose is 0.25 to 0.5mg every 2 to 8 days. Children aged 5 to 12 Initially 0.25 to 1mg administered intramuscularly years: daily; the maintenance dose is 0.25 to 1mg every 2 to 8 days. Elderly: There is no evidence to suggest that dosage should be different in the elderly. Diagnostic use:

Adults:

In cases of suspected adrenocortical insufficiency, where the 30-minute diagnostic test with Synacthen ampoules (see Synacthen Ampoules Summary of Product Characteristics) has yielded inconclusive results or where it is desired to determine the functional reserve of the adrenal cortex, a 5-hour test with Synacthen Depot may be performed. This test is based on measurement of the plasma cortisol concentration before and exactly 30 minutes, 1, 2, 3, 4 and 5 hours after an intramuscular injection of 1mg Synacthen Depot. If adrenocortical function is normal, baseline plasma

cortisol (normally >200 nmol/L) doubles in the first hour and then continues to rise slowly, as follows: Table Hourly cortisol levels: Time

nmol/L

1st hour 2nd hour 3rd hour 4th hour 5th hour

600 – 1250 nmol/L 750 – 1500 nmol/L 800 – 1550 nmol/L 950 – 1650 nmol/L 1000 – 1800 nmol/L

If plasma cortisol rises more slowly than indicated above, this may be the result of Addison's disease, secondary adrenocortical insufficiency due to a disorder of hypothalamo-pituitary function, or overdose of corticosteroids. A 3-day test with Synacthen Depot may be used to differentiate between primary and secondary adrenocortical insufficiency.

Children: Elderly:

All the plasma samples should be stored in a refrigerator until plasma cortisol level estimation. No paediatric dosage has been established. There is no evidence to suggest that dosage should be different in the elderly.

2. Storage Synacthen Depot should be stored in a refrigerator (2-8°C), in the original package. 3. Disposal Any unused product or waste material should be disposed of in accordance with local requirements.

Frequently asked questions about Synacthen Depot Ampoules 1 mg/ml

How do I take Synacthen Depot Ampoules 1 mg/ml?

Synacthen Depot Ampoules 1 mg/ml comes as injection containing 1mg/ml. Always follow the dose your doctor or pharmacist has given you, and read the leaflet that comes with the medicine.

What is the active substance in Synacthen Depot Ampoules 1 mg/ml?

The active substance in Synacthen Depot Ampoules 1 mg/ml is tetracosactide acetate.

Where does this information come from?

This leaflet reproduces the patient information leaflet approved for Synacthen Depot Ampoules 1 mg/ml, as published on the electronic medicines compendium (emc). The version printed inside your medicine’s packaging is the one that applies to you.

Can I get Synacthen Depot Ampoules 1 mg/ml without a prescription?

Whether a medicine is available over the counter or on prescription only depends on its licence. Check the leaflet, or ask your pharmacist — they can tell you straight away.

About this leaflet

The text above reproduces the patient information leaflet approved for this medicine, restructured for easier reading.

Medical disclaimer: This page is for information only and does not replace advice from your doctor or pharmacist. Always read the leaflet supplied with your medicine. If you are unwell, call NHS 111; in an emergency, call 999.

Medicines with the same active substance: Tetracosactide acetate (2 medicines)
See every medicine containing this substance, or browse the full A–Z of active substances.
⚕For healthcare professionals — Summary of Product Characteristics (SmPC)Full SmPC: dosage, interactions, contraindications, warnings+
Technical information intended for healthcare professionals (doctors and pharmacists). The Summary of Product Characteristics (SmPC) is the official document approved by the MHRA/EMA. It does not replace the patient leaflet or a doctor’s advice.

4.1. Therapeutic indications

Therapeutic use: Synacthen Depot should normally only be used for short-term therapy in conditions for which glucocorticoids are indicated in principle, for example, in ulcerative colitis and Crohn's disease, juvenile rheumatoid arthritis, or as adjunct therapy in patients with rheumatoid arthritis and osteoarthrosis. Synacthen Depot may be particularly useful in patients unable to tolerate oral glucocorticoid therapy or in patients where normal therapeutic doses of glucocorticoids have been ineffective.

Diagnostic use: As a diagnostic aid for the investigation of adrenocortical insufficiency.

4.2. Posology and method of administration

Posology

Therapeutic use: Initially, daily doses of Synacthen Depot should be given but after approximately 3 days, intermittent doses may be given.

Adults: Initially 1mg intramuscularly daily or 1mg every 12 hours in acute cases. After the acute symptoms of the disease have disappeared, treatment may be continued at a dose of 1mg every 2 to 3 days; in patients who respond well, the dosage may be reduced to 0.5mg every 2 to 3 days or 1mg per week.

Children aged 3 to 5 years: Initially 0.25 to 0.5mg intramuscularly daily; the maintenance dose is 0.25 to 0.5mg every 2 to 8 days.

Children aged 5 to 12 years: Initially 0.25 to 1mg intramuscularly daily; the maintenance dose is 0.25 to 1mg every 2 to 8 days.

Elderly:

There is no evidence to suggest that dosage should be different in the elderly.

Diagnostic use: In cases of suspected adrenocortical insufficiency, where the 30-minute diagnostic test with Synacthen ampoules (see Synacthen Ampoules 250 mcg Summary of Product Characteristics) has yielded inconclusive results or where it is desired to determine the functional reserve of the adrenal cortex, a 5-hour test with Synacthen Depot may be performed.

Adults: This test is based on measurement of the plasma cortisol concentration before and exactly 30 minutes, 1, 2, 3, 4 and 5 hours after an intramuscular injection of 1mg Synacthen Depot. If adrenocortical function is normal, baseline plasma cortisol (normally >200 nmol/L) doubles in the first hour and then continues to rise slowly, as follows:

Hourly cortisol levels:

Time

nmol/L

1st hour

600 – 1250 nmol/L

2nd hour

750 – 1500 nmol/L

3rd hour

800 – 1550 nmol/L

4th hour

950 – 1650 nmol/L

5th hour

1000 – 1800 nmol/L

If plasma cortisol rises more slowly than indicated above, this may be the result of Addison's disease, secondary adrenocortical insufficiency due to a disorder of hypothalamo-pituitary function, or overdose of corticosteroids.

A 3-day test with Synacthen Depot may be used to differentiate between primary and secondary adrenocortical insufficiency.

All the plasma samples should be stored in a refrigerator until plasma cortisol level estimation.

Children: No paediatric dosage has been established

Elderly: There is no evidence to suggest that dosage should be different in the elderly.

Method of administration

Synacthen Depot is intended for intramuscular injection. The ampoule should be shaken before use.

4.3. Contraindications

Hypersensitivity to tetracosactide or ACTH or to any of the excipients listed in section 6.1 List of excipients.

In view of the increased risk of anaphylactic reactions, Synacthen Depot should not be used in patients known to have asthma and/or other forms of allergy (see section 4.4 Special warnings and precautions for use).

Acute psychoses, infectious diseases, Cushing's syndrome, peptic ulcer, refractory heart failure, treatment of primary adrenocortical insufficiency and adrenogenital syndrome.

Synacthen Depot must not be administered intravenously.

4.4. Special warnings and precautions for use

Before using Synacthen Depot, the doctor should make every effort to find out whether the patient is suffering from, or has a history of, allergic disorders. In particular, he should enquire whether the patient has previously experienced adverse reactions to ACTH, Synacthen Depot or other drugs.

Synacthen Depot should only be administered under medical supervision.

If local or systemic hypersensitivity reactions occur during or after an injection (for example, marked redness and pain at the injection site, urticaria, pruritus, flushing, faintness, severe malaise or dyspnoea), Synacthen Depot or other ACTH preparations must be discontinued and should be avoided in the future. Hypersensitivity reactions tend to occur within 30 minutes of the injection. The patient should therefore be kept under observation during this time.

Preparation should be made in advance to combat any anaphylactic reaction that may occur after an injection of Synacthen. In the event of a serious anaphylactic reaction, the patient should be treated appropriately with adrenaline and steroids.

Synacthen Depot should not be used in the presence of active infectious or systemic diseases, when the use of live vaccine is contemplated or in the presence of a reduced immune response, unless adequate disease specific therapy is being given.

Use with care in patients with non-specific ulcerative colitis, diverticulitis, recent intestinal anastomosis, kidney failure, hypertension, thromboembolic tendencies, osteoporosis and myasthenia gravis.

High volumes should be used with caution and only if necessary, especially in subjects with liver or kidney impairment because of the risk of accumulation and toxicity (metabolic acidosis).

The increased production of adrenal steroids may result in corticosteroid type effects:

- Salt and water retention can occur and may respond to a low salt diet. Potassium supplementation may be necessary during long term treatment

- Psychological disturbances may be triggered (e.g. euphoria, insomnia, mood swings, personality changes and severe depression, or even frank psychotic manifestations). Existing emotional instability or psychotic tendencies may be aggravated

- Use cautiously in patients with ocular herpes simplex owing to possible corneal perforation

- Synacthen Depot may activate latent amoebiasis. It is therefore recommended that latent or active amoebiasis be ruled out before initiating therapy.

- If Synacthen Depot is indicated in patients with latent tuberculosis or tuberculin reactivity, close observation is necessary because the disease may be reactivated. During prolonged therapy, such patients should receive chemoprophylaxis.

- Ocular effects may be produced (e.g. glaucoma, cataracts).

- Provided the dose is chosen to meet the individual's needs, Synacthen Depot is unlikely to inhibit growth in children. Nevertheless, growth should be monitored in children undergoing long-term treatment. In infants and children aged up to 5 years, reversible myocardial hypertrophy may occur in very rare cases following long-term treatment with high doses. Therefore echocardiographic recordings should be made regularly.

- Dosage adjustments may be necessary in patients being treated for diabetes or hypertension.

An enhanced effect of tetracosactide acetate therapy may occur in patients with hypothyroidism and in those with cirrhosis of the liver.

In patients who suffer an injury or undergo surgery during or within one year after treatment, the associated stress should be managed by an increase in or resumption of treatment with Synacthen Depot. Additional use of rapidly acting corticosteroids may be required. Use the lowest effective dose to control the condition under treatment. If the dose has to be reduced, this should be done gradually. Relative insufficiency of the pituitary-adrenal axis is induced by prolonged administration, and may persist for several months after stopping treatment, so appropriate adrenocortical therapy should be considered.

Synacthen Depot contains less than 1 mmol sodium (23 mg) per ampoule, i.e. essentially 'sodium- free'.

Lack of diagnostic accuracy

Post administration total plasma cortisol levels during Synacthen test might be misleading in some special clinical situations due to altered cortisol binding globulin levels. These situations include patients on oral contraceptives, post operative patients, critical illness, severe liver disease, nephrotic syndrome. Hence in these circumstances, alternative parameters (e.g., salivary cortisol, free cortisol index, plasma free cortisol) can be used to assess the integrity of HPA axis.

4.5. Interaction with other medicinal products and other forms of interaction

Interactions are likely with drugs whose actions are affected by adrenal steroids (see Section 4.4 Special warnings and precautions for use).

Severe jaundice has been observed for concurrent use of Synacthen and valproate in paediatric population. Their concurrent use should be avoided.

Concurrent use of Synacthen and other anticonvulsants (e.g. phenytoin, clonazepam, nitrazepam, phenobarbital, primidone) may increase the risk of liver damage thus, Synacthen should be used with caution at minimum possible doses and for minimum duration for concurrent treatment.

Endogenous and synthetic oestrogens can cause an increase in total cortisol levels and therefore, it is considered appropriate to use alternative methods (e.g., salivary cortisol, free cortisol index, plasma free cortisol) for interpretation of the results of the HPA axis examination (see Section 4.4 Special warnings and precautions for use).

Patients already receiving medication for diabetes mellitus or for moderate to severe hypertension must have their dosage adjusted if treatment with Synacthen Depot is started.

4.6. Fertility, pregnancy and lactation

Women of child bearing potential

No special recommendation

Pregnancy

There is a limited amount of data on the use of Synacthen in pregnant patients. Data from animal studies are insufficient with respect to reproductive toxicity. Synacthen should be used during pregnancy only if the expected benefit outweighs the potential risk to the foetus.

Breast-feeding

It is unknown whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when Synacthen is administered to a breastfeeding woman.

Fertility

There is no data available.

4.7. Effects on ability to drive and use machines

Patients should be warned of the potential hazards of driving or operating machinery if they experience side effects such as dizziness.

4.8. Undesirable effects

Since Synacthen Depot stimulates the adrenal cortex to increase the output of glucocorticoids and mineralocorticoids, side effects associated with excessive adrenocorticotropic activity may be encountered, as well as those related to tetracosactide.

The following undesirable effects have been derived from post-marketing experience via spontaneous cases reports and literature cases. Because these reactions are reported voluntarily from a population of uncertain size, it is not possible to reliably estimate their frequency which is therefore categorised as not known. Undesirable effects are listed according to system organ classes in MedDRA. Within each system organ class, undesirable effects are presented in order of decreasing seriousness.

Table 1 Undesirable effects (frequency not known) related to tetracosactide

Immune system disorders:

Hypersenstivity*

Endocrine disorders:

Adrenal haemorrhage

*Tetracosactide can provoke hypersensitivity reactions which tend to be more severe (anaphylactic shock) in patients susceptible to allergies (especially asthma). Hypersensitivity reactions may include skin reactions at the injection site, dizziness, nausea, vomiting, urticaria, pruritus, flushing, malaise, dyspnoea, angioneurotic oedema and Quincke's oedema (see Section 4.4 Special warnings and precautions for use).

Undesirable effects related to glucocorticoid and mineralocorticoid effects

The undesirable effects related to glucocorticoid and mineralocorticoid effects are unlikely to be observed with short-term use of Synacthen Depot as a diagnostic tool, but may be reported when Synacthen Depot is used for therapeutic indications.

Table 2 Undesirable effects (frequency not known) related to glucocorticoid and mineralocorticoid effects

Infections and infestations:

Abscess, infection susceptibility increased

Blood and lymphatic system disorders:

Leukocytosis

Endocrine disorders:

Cushing's syndrome, secondary adrenocortical and pituitary unresponsiveness, particularly in times of stress, e.g. after trauma, surgery or illness; menstruation irregular, carbohydrate tolerance decreased, hyperglycaemia, manifestations of latent diabetes mellitus, hirsutism

Metabolism and nutrition disorders:

Hypokalaemia, calcium deficiency, sodium retention, fluid retention, increased appetite, hypokalaemic alkalosis

Psychiatric disorders :

Mental disorder1

Nervous system disorders:

Convulsions, benign intracranial pressure increased with papilloedema usually after treatment, vertigo, headache

Eye disorders:

Intraocular pressure increased, glaucoma, posterior subcapsular cataracts, exophthalmoses.

Cardiac disorders:

Cardiac failure congestive

Reversible cardiac hypertrophy may occur in isolated cases in infants and small children treated over a prolonged period with high doses

Vascular disorders :

Vasculitis necrotising, thromboembolism, hypertension

Gastrointestinal disorders:

Pancreatitis, peptic ulcer with possible perforation and haemorrhage, oesophagitis ulcerative, abdominal distension

Skin and subcutaneous tissue disorders:

Skin atrophy, petechiae, ecchymosis, erythema, hyperhidrosis, acne, skin hyperpigmentation

Musculoskeletal and connective tissue disorders:

Aseptic necrosis of femoral and humeral heads, spinal compression fractures, muscle atrophy, myopathy, osteoporosis, muscular weakness, pathological fracture of long bones, tendon rupture.

General disorders and administration site conditions:

Hypersensitivity reactions2, growth retardation, weight increase, impaired healing.

Investigations:

Nitrogen balance negative due to protein catabolism, suppression of skin test reactions.

1Also see Section 4.4 Special warnings and precautions for use.

2Also see Section 4.4 Special warnings and precautions for use and Section 4.8 Undesirable effects (paragraph Undesirable effects related to tetracosactide).

Reporting of suspected adverse reactions

Reporting of suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme by connecting to the following website: www.mhra.gov.uk/yellowcard.

4.9. Overdose

Relating to therapeutic usage of Synacthen Depot:

Overdosage may lead to fluid retention and signs of excessive adrenocorticotropic activity (Cushing's Syndrome). In such cases, Synacthen Depot should either be withdrawn temporarily, given in lower doses or the interval between injections should be prolonged (e.g. 5 to 7 days).

Treatment: There is no known antidote. Treatment should be symptomatic.

🇷🇴 Known in Romania as

Medicines sold in Romania with the same active substance: Cunoscut în România ca

  • SYNACTHEN 0,25 mg/1ml prescriptionTETRACOSACTIDUM · injection / infusion

Same active substance. The strength, the form and whether you need a prescription can differ. Always ask a pharmacist before you switch. Romanian medicines in the UK →

🇵🇱 Known in Poland as

Medicines sold in Poland with the same active substance: W Polsce znany jako

  • CosacthenTetracosactidum · injection / infusion

Same active substance. The strength, the form and whether you need a prescription can differ. Always ask a pharmacist before you switch. Polish medicines in the UK →

💬 Ask about this leaflet

Ask anything about Synacthen Depot Ampoules 1 mg/ml. The assistant answers only from this leaflet — if the leaflet does not cover it, it will say so. It does not give medical advice.

Answers come from the patient leaflet published on the electronic medicines compendium (emc). They are not medical advice. Ask a pharmacist or your GP if you are unsure. For urgent help call NHS 111, or 999 in an emergency.

Medicines containing Tetracosactide acetate

Pharmacies in major towns and cities — see the list
Pharmacies by county and region — see the full list

Browse all 2,009 towns and cities →